PLCG2 and acute lymphoblastic leukemia: Nalm-6 B-ALL cells were first treated with different PLC inhibitors, i.e., U73122, edelfosine, 3-Nitrocoumarin, SPK-601, D609, and manoalide, which all significantly decreased PLCγ2 constitutive activity, even at low concentration (Supplementary Fig. 2a, b), without affecting PLCγ2 protein levels (Supplementary Fig. 2c).